Herbert Loong, Clinical Associate Professor at The Chinese University of Hong Kong, shared on X about a recent paper by Koichi Goto et al. published on JTO:
“Our report of Asian subgroup data of LIBRETTO431: selpercatinib vs. ChemoIO first line treatment in RET Fusion Positive NSCLC has been published in IASLC
JTOCRR. 54% of this global trial were from East Asia . Results consistent with overall population and further echos the importance of early identification through molecular profiling in Asia.
Full paper can be found here.”
Title: First-line Selpercatinib or Chemotherapy and Pembrolizumab in Patients From East Asia With RET Fusion–Positive NSCLC: A LIBRETTO-431 Subgroup Analysis
Authors: Koichi Goto, Herbert H. Loong, Caicun Zhou, Kazumi Nishino, Dae Ho Lee, Se-Hoon Lee, James Chih-Hsin Yang, Dan Liu, Minji Kim Uh, Hongmei Han, Tarun Puri, Aimee Bence Lin, Ying Cheng
More posts featuring Herbert Loong.
